ABSTRACT
There are several well-described and named patterns of gastric mucosal inflammation. Helicobacter pylori gastritis has superficial plasmacytosis, deep lymphoid follicles, and neutrophils in the epithelium of the pits and the necks of the mucosa while deeper inflammation is much less common. Autoimmune atrophic gastritis, or simply autoimmune gastritis (AIG), is limited to oxyntic mucosa and has more basal lamina propria inflammation, oxyntic gland destruction with resultant mucosal atrophy, mucus gland and intestinal metaplasia, and enterochromaffin-like (ECL) cell hyperplasia. Longstanding H pylori gastritis can also be followed by glandular atrophy with intestinal metaplasia that can be limited to the antrum or be more widespread throughout the stomach, the latter termed multifocal atrophic gastritis. Lymphocytic gastritis has superficial plasmacytosis in the lamina propria and lymphocytes invading the surface and superficial pit epithelium. Some of these patterns have specific clinical associations that might affect patient management, stressing the importance of making the diagnosis of a specific gastritis whenever possible. For instance, H pylori gastritis is associated with peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma, and adenocarcinoma. Autoimmune gastritis is associated with anti-parietal cell and anti-intrinsic factor autoantibodies, anemia (both microcytic and macrocytic), small neuroendocrine (carcinoid) tumors, and a small but increased risk of dysplasia and carcinoma. Lymphocytic gastritis is classically associated with gluten-sensitive enteropathy (celiac disease).
In our practice, we have seen gastric biopsy specimens with an unusual pattern of inflammation different from the major gastritides with accepted names and known etiologies. These cases have chronic inflammation centered in the middle and deep zones of the mucosa involving the neck and gland zones, in contrast to H pylori gastritis, which has most intense inflammation in the superficial foveolar zone. They are also different from AIG and multifocal atrophic gastritis because there is less gland atrophy and no ECL cell hyperplasia. We could not find a description of this unusual but impressive mid-and deep-zone gastritis (MDZG) or its clinical associations, if any, in the published literature. We therefore decided to study these cases in more detail to see if they were part of a clinicopathologic syndrome.
Materials and Methods
Gastric biopsy specimens with a shared pattern of chronic inflammation (defined by the presence of plasma cells and lymphocytes in the lamina propria) localized to the mid-and deep zones of the mucosa and sparing of the superficial mucosal compartment were set aside in the course of gastrointestinal pathology diagnostic practice at the University of Michigan between 1994 and 2014. These biopsy specimens were reviewed by all three authors, who were blinded to the patient's identity and clinical history. Cases with recognizable AIG features, including ECL cell hyperplasia, were excluded from the study. Cases in which other causes of inflammation could be identified, such as H pylori organisms or viral cytopathic effect, were also excluded. A total of 28 H pylori-negative cases fulfilled the selection criteria and were included in the MDZG study group. Samples were obtained of both oxyntic and pyloric mucosa in 15 (54%) cases, only oxyntic mucosa in six (21%) cases, and only antral or antral and transitional zone mucosa in seven (26%) cases. The control group was 61 consecutive patients who had an upper gastrointestinal endoscopy in 2013 and whose gastric biopsy specimens had no significant inflammation. Although the control group was accrued over a shorter time interval compared with the MDZG group, most of the MDZG cases were recent biopsy specimens (18 [64%] of 28 MDZG cases were from 2011-2014), and hence the comparisons between the clinical backgrounds of the two groups are likely to be valid.
The following histopathologic features were analyzed for each study case: type of gastric mucosa involved by inflammation (body and/or antrum), composition and distribution of the inflammatory cell infiltrate, infiltration of gland epithelium by lymphocytes and gland destruction, neutrophils in the epithelium (activity), presence of lymphoid aggregates, and presence of metaplastic epithelium.
All cases were stained with antibodies against H pylori (prediluted, rabbit monoclonal clone SP48; Ventana Medical Systems, Tucson, AZ). Cases with corpus-dominant inflammation were also stained for chromogranin A to evaluate for ECL cell hyperplasia not visible on H&E (prediluted, mouse monoclonal clone LK2H10; Ventana Medical Systems). Immunohistochemistry for gastrin was performed in some cases to aid in the identification of antral mucosa among biopsy pieces (prediluted, rabbit polyclonal; Cell Marque, Rocklin, CA). All immunohistochemistry was performed on a Ventana automated staining platform according to the manufacturer's instructions.
Clinical records of the study and control cases were reviewed for demographic data, medical and surgical history, presenting symptoms/indications for endoscopy, endoscopic findings, and medications. The records were also searched for results of H pylori stool antigen and serologic tests and for autoimmune serologies. The clinical variables were analyzed for any patterns associated with the histologic findings. Statistical evaluation was performed using the Fisher exact test and Student t test. This study was approved by the Institutional Review Board of the University of Michigan.
Results

Histologic Findings
❚Table 1❚ lists the histologic finding and medical histories of all 28 MDZG cases. To reemphasize, the main histologic feature common to all cases was an inflammatory infiltrate in the lamina propria around the "mucous necks" and glands without any significant extension of inflammation into the foveolar compartment. The inflammation appeared "bottom-heavy" at low power ❚Image 1A❚, sometimes extending to the muscularis mucosae. The intensity and the composition of the inflammatory infiltrate were variable. In most cases, the infiltrate was predominantly mononuclear, composed of a mixture of lymphocytes and plasma cells. Some cases were dominated by plasma cells ❚Image 1B❚. Similarly, most cases had some eosinophils in the lamina propria, but three cases had an eosinophil-rich infiltrate with eosinophils easily identified at low magnification. Approximately half of all MDZG cases had basally located lymphoid aggregates, but only two cases had true lymphoid follicles with germinal centers.
Differences in the Inflammation in Oxyntic vs Antral Mucosa
Among the 15 cases with biopsy specimens of both oxyntic and antral mucosa, five cases had inflammation confined to antral mucosa, two cases had inflammation ❚Table 1❚ (cont) ❚Image 1❚ Manifestations of mid-and deep-zone gastritis (H&E stains). The low-magnification impression is of a "bottom-heavy" inflammatory infiltrate, with relative sparing of the lamina propria in the pit compartment of the mucosa nearest the lumen (A, ×4). Some cases had a predominantly plasma cell infiltrate, in this case involving oxyntic mucosa (B, ×40). Cases involving only the antrum tended to have neutrophilic (active) inflammation involving the glands and "mucus neck" regions (C, ×40), and one such case also had many neutrophils in the lamina propria (D, ×40). Cases involving both oxyntic and antral mucosa tended to have less intense inflammation in the antral mucosa (E, ×10).
confined to oxyntic mucosa, and eight cases had inflammation in both oxyntic and antral mucosa ❚Table 2❚. Cases of antrum-only gastritis differed from cases of gastritis in oxyntic mucosa. These antral-only cases tended to have active inflammation with neutrophils in the pyloric glands and foveolar necks ❚Image 1C❚ in addition to chronic lamina propria inflammation. One case of antral gastritis had a particularly neutrophil-dominant infiltrate in the lamina propria ❚Image 1D❚. Activity was much less common in cases with MDZG involving oxyntic mucosa and also less intense. In the eight cases with gastritis in both types of mucosa, the inflammatory infiltrate in the antrum was mononuclear without activity and less intense than in the oxyntic mucosa ❚Image 1E❚.
Gland-Destructive Inflammation
In addition to the inflammation in the lamina propria, most cases of oxyntic MDZG also had inflammatory cells, mainly lymphocytes, infiltrating gland epithelium, either in isolated foci or diffusely ❚Image 2A❚. One case of MDZG (case 10) was particularly intense with a dense lymphocytic infiltrate obscuring gland epithelium ❚Image 2B❚. Where there was parietal cell injury and loss, there was expansion of the neck compartment, that is, expansion of the proliferative zone, often with foveolar hyperplasia ❚Image 2C❚. In cases where loss of glandular epithelium was less pronounced, the glands were lined by a mixture of regenerative neck cells, chief cells, and injured parietal cells ❚Image 2D❚ and ❚Image 2E❚. No cases had intestinal or pyloric gland metaplasia in the oxyntic mucosa. Three cases had focal intestinal metaplasia in the antrum. All cases of gastritis in the oxyntic mucosa were evaluated for ECL cell hyperplasia with chromogranin immunostain. There was a range in the number of ECL cells, but no cases had more than the five cells in a row currently suggested as the minimum number needed for linear ECL cell hyperplasia. 1 
Gastritis Cases With Multiple Time Points
Five study patients had gastric biopsies performed on more than one occasion. Case 9 had multiple upper endoscopies during a 7-year period of follow-up for esophageal pemphigoid. The first gastric biopsy specimen in this follow-up period is the index biopsy specimen included in this study, and it has antral MDZG. The patient subsequently had seven additional endoscopies and gastric biopsies. Gastritis similar to the first biopsy specimen was present 2 months later. One and 2 years later, there was no inflammation, but 3 years later, there was mild inflammation and focal loss of pyloric glands in the antrum. One and 2 years subsequent to that, there was no inflammation but there was focal intestinal metaplasia in the antrum.
Case 10 is the biopsy specimen with the most intense inflammation in the oxyntic mucosa of the entire study group (Image 2B). A follow-up biopsy 9 months later had minimal inflammation, but the biopsy specimen was too small for definitive evaluation. Case 15 is a patient with recurrent episodes of abdominal pain and nausea that resulted in multiple gastric biopsies and hospitalizations over the follow-up course of 12 years. The index biopsy specimen is the latest biopsy specimen in this period, and it has active gastritis in the antrum. The same active antral gastritis was present 7 years earlier. However, an intervening biopsy specimen (5 years earlier than the index biopsy) had no gastritis. There was also no inflammation in biopsies taken 8 and 11 years earlier. Case 18 had gastric biopsies 3 months after the index biopsy, and the MDZG was unchanged in both oxyntic and antral mucosae. Case 21 is also a patient with a longstanding history of abdominal pain who had MDZG in both oxyntic and antral mucosa. A biopsy 8 years earlier had no inflammation. From this limited available information on the natural history of patients with this disease pattern, it appears that some cases resolve, some persist unchanged, and some vary over the course of time.
Clinical Findings
Demographic, endoscopic, and clinical variables of gastritis and control cases are compared in ❚Table 3❚.
Patient Demographics
Pathology reports with demographic data were available on all patients. Clinical records were either absent or incomplete in three MDZG cases. The study group had 21 females and 7 males, with ages ranging from 14 to 82 years (median, 56.5 years). The control group had 37 females and 24 males, with ages ranging from 18 to 84 years (median, 55.5 years). The female predominance is reflective of the patient population who undergoes upper endoscopy with biopsies at our institution. 2 Although the proportion of females in the MDZG group was higher than in the control group (75% vs 60%), the difference was not statistically significant.
Endoscopic Findings
Erythema was the most common endoscopic finding in both the study and control groups. The next most common finding in the control group was normal mucosa, but this was less likely to occur in the study group. Erosions or ulcers were the second most common finding in the study group and the third most common in the control group. Endoscopic reports for both groups included other descriptors such as "mucosal atrophy," "nodularity," "granular mucosa," "congested mucosa," and "portal hypertensive gastropathy." None of the endoscopic findings had a statistically significant correlation with the MDZG group.
Medical History
Autoimmune diseases as a group were more common in patients with MDZG than in the control group patients (Table 2) , and this difference was statistically significant (P < .001). Eight (29%) of patients ❚Image 2❚ Gland injury in mid-and deep-zone gastritis (H&E stains unless otherwise noted). Most cases in the series had a component of gland-infiltrative and sometimes gland-destructive inflammation. Typically, this was lymphocytic (A, ×40), and it was sometimes very intense with obscuration and/or loss of the gland epithelium (B, ×40). In cases with loss of parietal cells, there was expansion of the proliferative zone of the mucosa and foveolar hyperplasia (C, ×10). More intact glands had a regenerative appearance (D, E, ×10).
with MDZG had one or more autoimmune disease(s) ❚Table 4❚. The specific diseases were type 1 diabetes (two cases), systemic lupus erythematosus (two cases), Sjögren syndrome (two cases), and one case each of rheumatoid arthritis, primary biliary cirrhosis, autoimmune hepatitis, warm autoimmune hemolytic anemia, and esophageal pemphigoid. Four patients with MDZG (aged 24, 59, 60, and 84 years) had hypothyroidism that was not postsurgical. The 24-year-old patient in this group was also one of the patients with systemic lupus erythematosus. Five patients in the control group, all older than 60 years, also had hypothyroidism. Only two (3%) patients in the control group had autoimmune diseases: an 84-year-old woman had vitiligo and a 31-year-old man had a history of Graves disease; this last patient had hypothyroidism after ablation therapy.
Patients with MDZG were also more likely than controls to have positive autoimmune serologies. Autoantibody tests had been performed in 12 (43%) patients with MDZG and in 22 (36%) control group patients. Eight patients (67% of those tested) with MDZG were positive for one or more autoantibodies compared with only two control group patients (9% of those tested). The autoantibodies in patients with MDZG include antinuclear antibody (ANA, six cases), antimitochondrial antibody (AMA, two cases), anti-smooth muscle antibody (ASMA, one case), liver-kidney microsomal antibody (LKM, one case), and anti-parietal cell antibody (APC, one case). The APC-positive patient also had elevated ANA, AMA, and ASMA antibody titers and had a diagnosis of autoimmune hepatitis (case 16). No other patient in either the study or control group had anti-parietal cell antibodies measured. Serum gastrin levels were not available for any patient. Four patients with MDZG with autoantibodies were the same patients who had autoimmune diseases, but four were not. Three patients with MDZG without autoimmune disease had elevated ANA. The other patient with MDZG without autoimmune disease had hepatitis C and was positive for LKM antibody. The two patients with autoantibodies in the control group were a 26-year-old woman with epigastric pain and migraine headaches who had an ANA titer of 1:640 and a 71-year-old woman with gastroesophageal reflux disease and hypothyroidism who had an ANA titer of 1:320.
No other disease associations were detected in the patients with MDZG. Four patients with MDZG had cirrhosis, in two cases secondary to hepatitis C, compared with two patients with cirrhosis secondary to nonalcoholic steatohepatitis in the control group. These differences in liver disease were not statistically significant. Patients with MDZG were no more likely than controls to be hospitalized.
Evidence of Prior H pylori Infection
Only a few patients in the MDZG or the control group had testing for antibodies against H pylori. In the MDZG group, seven (25%) patients had testing. MDZG case 28 had a positive H pylori serology and received triple therapy prior to any biopsy. The other six MDZG cases had negative H pylori serologies. MDZG case 6 had a mention ❚Image 2❚ (cont) No cases had the type of enterochromaffin-like cell hyperplasia typical of autoimmune gastritis (F, ×10, chromogranin stain). of H pylori gastritis occurring 7 years earlier, but no serologic studies (or any other clinical records) were available in this case. In the control group, 13 (21%) patients had testing. One patient was positive and received the Prevpac treatment 1 year earlier. The other 12 patients were negative. One additional control group patient had a mention of prior H pylori gastritis in her clinic notes.
Medications
Medication histories in both groups were varied, but we did not discern a specific pattern of use for any particular drug or class of drugs that distinguished the gastritis group. In MDZG case 13, the clinician suspected that the patient's presenting symptoms of nausea, vomiting, and diarrhea were a reaction to topiramate used to treat migraine symptoms. Symptoms resolved when topiramate was stopped, but there was no follow-up biopsy. Several patients in the control group were also taking topiramate. Nonsteroidal anti-inflammatory drug (NSAID) use was specifically mentioned in the clinical notes for two gastritis cases, both antral. However, many patients in the control group were also taking NSAIDs and/or daily aspirin. The rate of proton-pump inhibitor (PPI) use was not significantly different between the two groups.
Discussion
With the decreasing prevalence of H pylori in the West, fewer biopsies specimens of specific types of gastritis are seen, and much of the gastritis we see is a collection of histologic changes with no clinical context. [3] [4] [5] [6] [7] H pylori gastritis, AIG, and lymphocytic gastritis are specific patterns of inflammation, but we have been seeing other unnamed gastritides with predictable histologic patterns that have no known clinical association(s). In the past 20 years of diagnostic practice, we have been particularly impressed with the pattern of MDZG in which the inflammatory infiltrate is concentrated in the gland compartment rather than the superficial foveolar compartment.
Inflammation in the glandular compartment of oxyntic mucosa without significant glandular atrophy and only limited mucus gland and intestinal metaplasia has been reported in patients with hypergastrinemia and serologic markers of AIG. Stolte et al 8 intestinal, pyloric gland, or pancreatic acinar cell metaplasia, a finding that is usually associated with atrophy in oxyntic mucosa. ECL cell hyperplasia stimulated by increased gastrin production is another marker of AIG. Stolte et al 8 found neuroendocrine cell hyperplasia on H&E in 22% of their study cases, while Torbenson et al 9 found ECL cell hyperplasia, at least linear, in all cases. The inflammatory infiltrate surrounding oxyntic glands in MDZG with foci of gland destruction is certainly similar to what is seen in AIG, but there are also differences. None of the cases in our study had any metaplasia in the oxyntic mucosa. There was also no ECL hyperplasia in the MDZG cases, proven by chromogranin staining ❚Image 2F❚. A few cases had an increased number of ECL cells possibly in the range of what has been termed simple ECL cell hyperplasia. 1 However, simple ECL cell hyperplasia is not specific for autoimmune gastritis and has been reported in patients on PPI therapy. 10, 11 In most of the cases of MDZG in oxyntic mucosa in which antral biopsies were also taken, the inflammation in antral mucosa was less intense or not present. Antral inflammation has been observed in AIG. Stolte et al 8 reported minimal inactive superficial antral gastritis as the most common type of inflammation in the antrum in cases with active AIG, a finding that is similar to H pylori gastritis that has been treated. 12, 13 Torbenson et al 9 reported chronic antral gastritis, both active and inactive, in half of their study cases. It is possible that at least some of the MDZG cases in our series may be early AIG, which
had not yet developed diagnostic morphology, but none of the cases with follow-up biopsies had features indicating the development of AIG. Four MDZG cases had antrum-exclusive gastritis with sparing of oxyntic mucosa. Three of these cases had significant neutrophil activity. Two additional cases had similar active antral gastritis, but oxyntic mucosa was not biopsied. These cases of active antral gastritis differ from MDZG involving oxyntic mucosa as the latter has little activity and instead has gland destruction by mononuclear cells. They also lack the association with autoimmunity seen with MDZG in the body and may therefore be a different entity.
Compared with the control group, patients with MDZG were significantly more likely to have autoimmune diseases and/or positive autoimmune serology (Table 2 ). Eight (29%) patients with MDZG had at least one autoimmune disease. Four of these patients also had positive autoimmune markers, and four additional patients had elevated autoimmune antibody titers. Thus, 12 of the 28 study patients had either autoimmune diseases, autoantibodies, or both. (The rate of autoantibody testing was similar in MDZG and control groups.) The autoimmune diseases encountered in patients with MDZG include systemic lupus erythematosus, type 1 diabetes, primary biliary cirrhosis, and Sjögren syndrome, all of which are associated with gastric autoimmunity. [14] [15] [16] [17] The patient with MDZG with anti-parietal cell antibodies had autoimmune hepatitis, which can also be associated with additional autoimmune manifestations. 18 Several patients in both groups had hypothyroidism. Although hypothyroidism is considered to have autoimmune etiology in young patients, changes in thyroid function in older adults may be part of the physiology of aging. 19 Since this condition occurred almost exclusively in older patients in both our study and control groups (apart from one young patient with both lupus and hypothyroidism), it was excluded from the category of autoimmune diseases in statistical analysis. Jevremovic et al 20 reported an association between autoimmune disease and a destructive, atrophic pangastritis that they termed "atrophic autoimmune pangastritis." It is possible that at least a subset of our cases (those with inflammation in both body and antral mucosa) may fit this diagnosis, although, for the most part, we did not see the same degree of mucosal atrophy illustrated in that study.
There is a complex relationship between AIG and H pylori infection. Some studies have demonstrated concurrent H pylori infection and serologic evidence of prior H pylori infection in patients who otherwise have features of AIG. [21] [22] [23] [24] Conversely, patients with H pylori gastritis can develop antigastric autoantibodies. 25 We found no significant association with current or past H pylori infection in the MDZG group. It should be noted, however, that only one-fourth of patients with MDZG had H pylori serologic testing.
Endoscopic findings had no association with histologic inflammation in this study. This is not surprising given the fact that some studies have suggested that there is a poor endoscopic-histologic correlation in the stomach. [26] [27] [28] This study has several important limitations. First, this is a retrospective study with inherent variability in the quality and completeness of available clinical data. The patients were not evaluated using a protocol-based approach to ensure that all of them were asked the same clinical question and had the same evaluations for antigastric antibodies and serum gastrin levels. As a result, we do not know if MDZG is associated specifically with antigastric autoimmunity or is a general manifestation of autoimmune disease in gastric mucosa. Second, the biopsies were not done according to a specific protocol, and for many cases, we do not know the distribution of MDZG in both oxyntic and antral mucosae. The fact that half of the cases with biopsies from both sites also had inflammation in both sites suggests that in about half of these patients, the disease is a pangastritis. However, given the extensive morphologic similarities and association with autoimmunity, it seems likely that our set of MDZG includes at least some cases of a type of autoimmune gastritis that differs from classic AIG. Active MDZG in the antrum appears to be an unrelated entity with a similar pattern of inflammation.
